Brainsway Q2 Earnings Call Highlights
BrainsWay (NASDAQ:BWAY) reported Q2 gross profit up 34% to $12.8M with gross margin at 75%. Management cited a 30% backlog increase and SWIFT reimbursement progress, estimating 57M US covered lives. CFO Ido Marom said operating cash flow was $6.3M and raised 2026 revenue guidance to $68M-$70M. The company is also discussing Neurolief’s ProlivRx soft launch.
How this was made
The 30-second read
Why it matters
Traders can update 2026 revenue expectations based on the raised guidance and assess adoption momentum via SWIFT reimbursement access and durability/real-world response data. The cash flow improvement and debt-free status reduce near-term balance-sheet risk, while the wide margin/EBITDA ranges and contingent Neurolief investment plan keep uncertainty elevated.
Market read
Raised 2026 revenue guidance, improved operating cash flow, and quantified SWIFT reimbursement access are the main catalysts for repricing expectations.
What to watch
Neurolief commercialization is described as a 90-day soft launch with investment decisions contingent on milestones, so near-term upside may depend on whether those commercial metrics materialize.
Background
BrainsWay’s Q2 earnings call highlights focused on Deep TMS reimbursement (SWIFT), clinical durability and real-world data, Neurolief commercialization, and updated 2026 financial guidance.
Ticker impact
BrainsWay raised 2026 revenue guidance to $68M-$70M and reported Q2 gross profit up 34% to $12.8M.
Likely positive bias for the next few sessions as traders price higher 2026 growth and reimbursement-driven adoption.
The article discloses multiple primary datapoints: raised revenue guidance, operating cash flow jump, debt-free balance, and reimbursement access estimates for SWIFT, all of which can move expectations. However, the margin and EBITDA outlook are given as broad ranges, limiting precision.
Market effects
Reimbursement progress for accelerated Deep TMS could strengthen sentiment toward non-invasive neuromodulation peers and the broader interventional psychiatry category.
US-focused reimbursement access estimate (57M covered lives) may drive US clinic adoption and payer negotiations.
Limited direct global impact in the text, as the reimbursement and VA channel commercialization are US-centric.
Counterpoint
The guidance raise may already be partially anticipated, and the margin/EBITDA outlook spans a very wide band, implying execution risk remains high.
Key entities
- companyBrainsWay
Non-invasive neuromodulation company; reported Q2 results, raised 2026 revenue guidance, and discussed SWIFT reimbursement and Neurolief commercialization.
- productSWIFT accelerated Deep TMS protocol
Protocol intended to reduce treatment duration from weeks to a few days; management cited reimbursement access and clinical durability/real-world response data.
- companyNeurolief
BrainsWay holds a minority interest via a convertible loan; Neurolief began commercializing its FDA-approved ProlivRx system with a VA-focused soft launch.
